Form 4: Iradimed CFO John Glenn Sells 2,500 Shares

Iradimed's Chief Financial Officer, John Glenn, sold 2,500 shares of common stock at a weighted average price of $54.1797 on December 2, 2024.

Summary

• John Glenn, the Chief Financial Officer of Iradimed Corporation, sold 2,500 shares of the company's common stock on December 2, 2024.
• The sale was executed in multiple trades with prices ranging from $54.00 to $54.22 per share.
• The weighted average price for the sale was $54.1797 per share.
• Following the transaction, Mr. Glenn directly owns 4,383 shares of Iradimed common stock.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating a routine stock sale by a company executive. It does not convey any positive or negative sentiment about the company's performance or future prospects.

Industry Context

This is a routine filing related to insider trading activity and is common for publicly traded companies. It does not indicate any specific trend in the medical device industry.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies and their executives.
• The sale of shares by a CFO is not unusual and can be for various personal financial reasons.
• The transaction is within the normal range of insider trading activity.

Stakeholder Impact

• The sale of shares by the CFO may have a minor impact on investor sentiment, but is unlikely to significantly affect the company's operations or financial health.

Key Dates

Keywords

Iradimed, IRMD, John Glenn, CFO, stock sale, insider trading, Form 4, equity securities